On a September morning in Groningen, a blood sample from a suspected sepsis patient lands on what looks like an unremarkable benchtop instrument. Inside, synthetic diamonds—each smaller than a grain of pollen—are about to attempt something conventional microscopes cannot: measure the fleeting burst of free radicals erupting inside individual immune cells.
The technology sounds like something from a science fiction pitch deck. Diamonds engineered with atomic defects. Quantum spin states responding to magnetic fields so faint they reveal reactive oxygen species inside a mitochondrion. A diagnosis rendered in minutes instead of hours, distinguishing deadly infections from less urgent inflammations by reading the metabolic signature of living cells.
Yet here it sits, installed in the emergency department at University Medical Center Groningen, scanning samples from real patients while clinicians wait to see if quantum physics can actually help them save lives.
This is nitrogen-vacancy diamond magnetometry, and it's emerged from an unlikely place: the collision between materials science, semiconductor inspection, and the nanoscale chaos of human biology. Investors should probably pay closer attention than they have.
When Physics Meets the Emergency Department
The science behind NV-diamond sensing has been around for years—mature, even—but the hardware is only now shrinking to clinical relevance. QT Sense, the Groningen-based spinout conducting that emergency department trial, raised €10 million since early 2025 to commercialize what it calls "single-cell Nano-MRI." The company describes something genuinely novel in a field cluttered with incremental improvements: label-free, live-cell measurements at subcellular resolution, with throughput edging toward what hospitals might actually use.
Perhaps more telling, the capital came from investors who aren't typically drawn to quantum moonshots. Cottonwood Technology Fund led the latest €4 million round in February 2026, joined by grants tied to the ONCO-Q colorectal cancer project and the Quantum Forward Challenge. QDNL Participations and angel investors supplied an earlier €6 million in 2025, alongside Interreg Europe grants.
The pitch breaks from the usual quantum sensing narrative. Most quantum diagnostics companies target organ-scale measurements—magnetocardiography mapping the heart's electrical activity, or magnetoencephalography scanning brain function. Those applications compete directly with established technologies and face well-worn regulatory pathways.
NV-diamond diagnostics occupy stranger territory. They measure individual cells. They track metabolic signatures invisible to conventional tools. And they lack obvious regulatory precedent, which means the path from research instrument to FDA-cleared diagnostic remains unclear.
That uncertainty hasn't stopped the science from advancing.
The Quantum Compass Inside a Diamond
Nitrogen-vacancy centers are exactly what they sound like: atomic-scale defects where a nitrogen atom sits next to a missing carbon in diamond's crystal lattice. These defects create quantum systems that behave, essentially, like tiny compasses.
Hit them with green light, and they fluoresce red. The brightness fluctuates with magnetic field strength. More precisely, the spin energy levels of the NV center shift in response to magnetism, electric fields, temperature, and strain—making them exquisitely sensitive reporters of their nanoscale environment.
The breakthrough came when researchers learned to fabricate fluorescent nanodiamonds small enough—5 to 100 nanometers across—for cells to internalize. Once inside, these diamonds measure paramagnetic species (unpaired electrons in free radicals, transition metals, molecular oxygen) via relaxometry, tracking how fast the quantum spin state decays.
A 2022 paper in Accounts of Chemical Research demonstrated this in primary human immune cells, measuring nitric oxide and superoxide production at the level of individual vesicles. By 2025, the Groningen group led by Professor Romana Schirhagl was publishing vesicle-specific radical dynamics across macrophage subtypes. The conflicts-of-interest disclosures now include QT Sense's founding.
Elsewhere, research has sprawled in multiple directions. Widefield "quantum diamond microscopes" image magnetic labels on cell surfaces or tissue sections. A 2015 Nature Methods paper showed single-cell biomarker quantification using immunomagnetic labels and ensemble NV sensors embedded in diamond chips; by 2022, the same approach had scaled to tumor tissue imaging. A 2024 preprint reported non-invasive magnetocardiography in rats using NV sensors with 9 pT/√Hz sensitivity—early proof the technology can operate beyond cellular scale.
The competitive landscape, though, is fragmented. And perhaps more competitive than it first appears.
The OPM Problem
Optically pumped magnetometers—which use alkali vapor cells rather than diamonds—currently dominate large-scale biomagnetism applications. And they're not waiting around.
Genetesis secured FDA 510(k) clearance and Health Canada approval for its CardioFlux MCG platform, a 90-second, non-contact scan for diagnosing myocardial ischemia. The company is enrolling multicenter trials. Cerca Magnetics and FieldLine Medical are commercializing OPM-MEG systems for brain imaging, with installations scaling to 100+ sensors. These remain research tools for now, but the regulatory path is visible. Investors can sketch timelines with some confidence.
NV-diamond diagnostics? Earlier stage by a fair margin.
QT Sense's Quantum Nuova platform is, bluntly, a research instrument. Confocal optics integrated with multi-well plates (up to 96 samples), designed for live-cell measurements of oxidative stress and radical kinetics. First placements focus on drug mechanism-of-action studies and exploratory oncology work—the kind of applications that generate data and publications but not revenue at scale.
The University Medical Center Groningen installed its system in September 2025 to investigate whether reactive oxygen species kinetics can serve as an early sepsis biomarker. That study is ongoing. Results aren't public. The question hanging over the emergency department pilot is straightforward: Can neutrophil or monocyte radical kinetics, measured from a blood draw, actually correlate with infection severity and patient outcomes?
If yes, the technology offers a functional biomarker complementing existing panels like procalcitonin or lactate. If the correlation proves weak—or confounded by inflammation from trauma, surgery, autoimmune disease—the clinical utility collapses.
No one's claiming certainty yet. Which is, at least, refreshingly honest.
Three Forces Driving Clinical Relevance
Several factors are accelerating NV-diamond sensing toward something resembling clinical deployment.
Materials quality is improving. Higher-purity nanodiamonds with extended spin coherence times (T1/T2) are commercially available. Ensemble NV sensors now approach sub-10 pT/√Hz sensitivity, competitive with SQUID magnetometers in certain regimes. A 2025 arXiv preprint described a 49-plex DNA microarray fabricated directly on diamond surfaces, using gadolinium displacement to restore T1 signal. Multiplexed biosensing is feasible, in other words, even if not yet routine.
Neuromorphic readout techniques—which reduce data volume and latency in widefield imaging—are moving from lab demonstrations to prototype hardware. The engineering is getting real.
Biological validation is accumulating. Schirhagl's lab alone has published on primary dendritic cells (donor-dependent NOX2 activity), sperm motility and oxidative damage, mitochondrial metabolism via targeted nanodiamonds, and nitric oxide sensing in single cells. A January 2025 Nature Communications paper validated a spin-enhanced nanodiamond lateral-flow test for SARS-CoV-2 in 103 clinical samples, showing improved early detection versus conventional gold-nanoparticle strips.
These aren't diagnostic products. Not yet. But they establish proof-of-concept across infectious disease, oncology, fertility, and inflammation—enough to suggest the technology isn't limited to one narrow application.
Funding is flowing. Unevenly, but flowing nonetheless.
QT Sense raised €6 million in February 2025 (equity from QDNL Participations and angels, plus Interreg Europe grants) and an additional €4 million in February 2026, led by Cottonwood Technology Fund, with non-dilutive support from the ONCO-Q colorectal cancer project and the Quantum Forward Challenge. NVision Imaging, which uses NV diamonds to hyperpolarize MRI tracers, raised $30 million in Series A funding in June 2023 and partnered with Siemens. Quantum Diamond Technologies in the U.S. is developing NV magnetic imaging for ultrasensitive biomarker detection, though it hasn't disclosed recent funding rounds.
Market forecasts remain scattershot, their methodologies often opaque. Future Market Insights projects the quantum sensors market growing from $400 million in 2025 to $1.7 billion by 2035 (roughly 15% CAGR), citing NV sensors as emerging contributors. IDTechEx forecasts the sector reaching $2.2 billion by 2045, covering OPMs, NV magnetometers, and SQUIDs. McKinsey's June 2025 Quantum Tech Monitor estimates quantum sensing could represent $7 billion to $10 billion within a $97 billion total quantum technology market by 2035.
The directional consensus is clear, anyway: sensing is transitioning from R&D to deployment. Whether those numbers prove accurate is another matter.
Inside the Commercialization Playbook
QT Sense offers the clearest view—perhaps the only clear view—of how NV-diamond diagnostics might actually commercialize.
The company's Quantum Nuova platform measures reactive oxygen and nitrogen species (ROS/RNS) in living cells by tracking the T1 relaxation time of fluorescent nanodiamonds. Cells internalize the particles. Confocal optics scan each well. Software converts fluorescence decay into radical concentration. The system handles 96-well plates, enabling moderate throughput for drug screening and cell biology work.
The oncology use case is straightforward enough. Cancer cells often exhibit elevated oxidative stress; metastatic cells differ metabolically from primary tumors. QT Sense claims its platform can distinguish colorectal cancer cell lines from healthy colonocytes based on ROS kinetics, and that NOX2 inhibitors produce measurable shifts in radical production. The ONCO-Q project—approximately €2 million in subsidy, announced October 2025—is validating these measurements in patient-derived samples at UMCG.
Sepsis, though, is trickier.
The UMCG emergency department pilot hinges on whether neutrophil or monocyte radical kinetics correlate with infection severity and outcomes. The stakes are higher. Sepsis kills roughly 11 million people annually worldwide; early identification saves lives. But the signal might prove too noisy. Inflammation from trauma, surgery, autoimmune conditions—all could confound the metabolic signature QT Sense is measuring.
Results aren't public. Clinicians are waiting.
CEO Deepak Veeregowda, in a February 2025 interview, framed QT Sense's advantage as single-cell resolution: "Other quantum sensing healthcare plays—OPM-based magnetocardiography, for instance—operate at organ scale. We're measuring individual cells, which matters when cell-to-cell heterogeneity drives disease progression."
Investor Ton van 't Noordende of QDNL Participations emphasized the team's "lab-to-product capability"—a polite acknowledgment that academic quantum sensing often stalls at the prototype stage, stranded between proof-of-concept and commercial viability.
The comparison to Genetesis is instructive. Its OPM-MCG platform scans a patient's chest in 90 seconds, generating a magnetic map of cardiac electrical activity without electrodes or contrast agents. The device received FDA 510(k) clearance and is enrolling trials for chest-pain triage in emergency departments. The value proposition is speed and non-invasiveness; the regulatory pathway is well-understood, relying on substantial equivalence to prior MCG systems.
NV-diamond diagnostics lack that precedent entirely.
Any assay QT Sense commercializes will likely navigate either the laboratory-developed test pathway—now under FDA scrutiny following the May 2024 final rule phasing out enforcement discretion—or the medical device route, which requires premarket review for most active diagnostic instruments. Neither path is quick. Neither is cheap.
The regulatory uncertainty alone could stall commercialization for years.
The Next 18 Months Will Tell
Clinical validation data from UMCG's sepsis study and the ONCO-Q colorectal project will clarify whether this technology remains a research tool or crosses into regulated diagnostics.
Positive results—defined as measurable sensitivity and specificity improvements over existing biomarkers—could catalyze partnerships with diagnostics incumbents like Roche, Abbott, or Siemens Healthineers. Or contract research organizations seeking differentiated cell-based assays. Negative or ambiguous results? The technology retreats to niche academic use.
Regulatory clarity matters as much as clinical data. The FDA's LDT final rule phases in device requirements through 2028, with labeling compliance expected by May 2025. Any quantum-enabled assay offered via CLIA labs will face increasing scrutiny: premarket review, quality systems, adverse event reporting. The FDA's January 2026 clinical decision support guidance also affects software interpreting ODMR (optically detected magnetic resonance) or relaxometry signals for clinical decisions.
Europe's MDR/IVDR classification pathways are similarly relevant. Active diagnostic devices typically fall into Class IIa, requiring conformity assessment and notified body involvement. Companies that underestimate these timelines risk burning capital chasing approvals that take longer than expected.
Assay specificity remains an open question—possibly the biggest technical hurdle. NV relaxometry responds to generic paramagnetic noise: ROS, RNS, gadolinium, molecular oxygen. That makes it sensitive but not inherently selective. Achieving clinical specificity requires clever assay design: targeted nanodiamonds localizing to specific organelles, paramagnetic tags that displace upon biomarker binding, nanocatalytic amplification schemes.
A 2025 arXiv preprint demonstrated a 49-plex microarray using gadolinium displacement. Future diagnostics may follow similar transduction strategies. Or they may hit fundamental limits in signal-to-noise ratios that make clinical translation impractical.
Throughput and workflow integration will determine adoption, assuming the science works. Confocal scanning trades speed for resolution; widefield imaging trades resolution for speed. Standardized nanodiamond functionalization, stable optical setups, compatibility with existing lab automation—these are prerequisites for pharma and biotech uptake. QT Sense's 96-well format is a start, but high-content screening platforms routinely process 384- or 1536-well plates.
Market growth will almost certainly be uneven. OPM-based magnetocardiography and magnetoencephalography are advancing faster, driven by clear clinical needs (chest-pain triage, pediatric epilepsy) and established reimbursement codes. NV-diamond diagnostics will likely enter via research services—drug mechanism-of-action studies, cell line characterization, immuno-oncology profiling—before attempting regulated claims.
Early-access placements, QT Sense's current strategy, serve dual purposes: generating revenue and collecting validation data for regulatory submissions. Whether that revenue scales to venture-backable returns is unclear.
Public funding remains robust, at least. The EU Quantum Flagship's 2030 roadmap prioritizes sensing alongside computing and communication, with potential grants for clinical validation consortia. The European Commission's July 2025 strategy explicitly positions quantum to impact healthcare, specifically faster disease diagnosis. National initiatives in the U.S., UK, and Germany are similarly active.
This creates a favorable environment for pilot studies and multi-institutional collaborations. It also risks over-promising on timelines—a familiar problem in quantum technologies.
The Investor Calculus
For investors, the calculation is straightforward, if unsatisfying.
NV-diamond sensing represents real science with early commercial traction. The technology offers something genuinely novel—label-free, live-cell measurements at nanoscale resolution—in a field crowded with incremental improvements. But clinical utility remains unproven outside narrow use cases. The regulatory pathway is uncertain. Throughput and workflow integration are question marks.
Companies that secure strong intellectual property, navigate regulatory pathways competently, and demonstrate reproducible clinical performance in well-designed studies will command premium valuations. Those that rely on research-use-only sales or struggle with assay standardization will face commoditization pressure as the technology matures and competitors emerge.
The upside, though, is genuinely differentiated. A fundamentally new way to interrogate biology at the scale where disease begins. Single-cell resolution that captures metabolic heterogeneity conventional tools miss. Functional readouts that could outperform static biomarker panels.
Whether that upside materializes depends less on quantum mechanics than on clinical validation, regulatory strategy, and workflow fit. Familiar challenges in any diagnostic technology—just with higher technical risk and longer timelines.
The diamonds, at least, are no longer confined to physics labs. They're scanning cells in a Dutch emergency department, measuring signals that might distinguish deadly infections from false alarms. Results from UMCG's sepsis study should arrive within 18 months. The ONCO-Q colorectal data will follow.
Until then, quantum diamond diagnostics remain precisely what they've always been: promising science with uncertain commercial outcomes. The difference now is that real patients are involved, real clinicians are waiting for results, and real capital is at risk.
The technology has left the lab. Whether it reaches broader clinical adoption—and whether investors who backed it early reap returns—will become clear soon enough.
